LENZ Therapeutics, Inc.
LENZ
$7.34
$0.050.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.90M | 1.59M | 12.50M | 5.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.90M | 1.59M | 12.50M | 5.00M | -- |
| Cost of Revenue | 1.08M | 418.00K | -- | -- | -- |
| Gross Profit | 825.00K | 1.17M | 12.50M | 5.00M | -- |
| SG&A Expenses | 44.96M | 39.63M | 27.60M | 12.80M | 11.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.04M | 40.05M | 31.39M | 21.86M | 16.93M |
| Operating Income | -44.14M | -38.46M | -18.89M | -16.86M | -16.93M |
| Income Before Tax | -41.49M | -35.89M | -16.70M | -14.41M | -14.62M |
| Income Tax Expenses | -- | 2.00K | -- | 500.00K | -- |
| Earnings from Continuing Operations | -41.49M | -35.90M | -16.70M | -14.91M | -14.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.49M | -35.90M | -16.70M | -14.91M | -14.62M |
| EBIT | -44.14M | -38.46M | -18.89M | -16.86M | -16.93M |
| EBITDA | -44.02M | -38.36M | -18.76M | -16.84M | -16.90M |
| EPS Basic | -1.32 | -1.16 | -0.59 | -0.53 | -0.53 |
| Normalized Basic EPS | -0.83 | -0.72 | -0.37 | -0.32 | -0.33 |
| EPS Diluted | -1.32 | -1.16 | -0.59 | -0.53 | -0.53 |
| Normalized Diluted EPS | -0.83 | -0.72 | -0.37 | -0.32 | -0.33 |
| Average Basic Shares Outstanding | 31.35M | 31.07M | 28.54M | 28.08M | 27.53M |
| Average Diluted Shares Outstanding | 31.35M | 31.07M | 28.54M | 28.08M | 27.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |